Sou Hu Cai Jing·2026-02-12 19:21Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Fosun Pharma (02196.HK) by 323,000 shares on February 12, 2026, marking a cumulative net reduction of 709,500 shares over the past five trading days [1][2] - Over the last 20 trading days, there have been 12 days of net increases in holdings by southbound funds, totaling an increase of 6,455,000 shares [1][2] - As of now, southbound funds hold 318 million shares of Fosun Pharma, which represents 57.61% of the company's total issued ordinary shares [1][2] Group 2 - Fosun Pharma is primarily engaged in the research, development, manufacturing, and sales of pharmaceutical products, operating through five segments [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccine business [2] - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic medical devices [2] - The healthcare services segment operates an integrated online and offline medical service platform [2] - The pharmaceutical distribution and retail segment is responsible for the wholesale and retail of pharmaceutical products [2] - The company's products are mainly used in the treatment fields of oncology, immunology, and central nervous system disorders [2]